研报掘金丨长城证券：达仁堂业绩弹性可期，维持“买入”评级

Core Viewpoint - Darentang reported significant profit growth in Q3, with strong performance from its fast-acting heart rescue pill [1] Sales Performance - In the first three quarters, the sales revenue of the fast-acting heart rescue pill (including tax) reached 1.716 billion yuan, representing a year-on-year increase of 13.34% [1] - The sales revenue of the throat-soothing pill (including tax) was 376 million yuan, showing a year-on-year growth of 38.61% [1] Strategic Focus - The company is focusing on product and market strategies under brand leadership, enhancing regional coverage and channel penetration [1] - The emphasis on fast-acting products has led to good growth in key categories [1] Future Outlook - The company has streamlined its operations by divesting non-core businesses, which provides ample room for future development in pharmaceutical resource utilization and cost reduction [1] - The performance elasticity is expected to be promising [1] Investment Rating - The company maintains a "Buy" rating based on its strong performance and growth potential [1]